Therapy Detail

Therapy Name G-631
Therapy Description

G-631 inhibits Tankyrase 1 and 2, resulting in decreased Wnt/Beta-catenin pathway signaling, but has little anti-tumor activity and leads to intestinal toxicity (PMID: 26692561).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
G-631 Tankyrase Inhibitor 9 G-631 inhibits Tankyrase 1 and 2, resulting in decreased Wnt/Beta-catenin pathway signaling, but has little anti-tumor activity and leads to intestinal toxicity (PMID: 26692561).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
APC mutant colorectal cancer no benefit G-631 Preclinical - Cell line xenograft Actionable In a preclinical study, G-631 inhibited Wnt pathway signaling in colorectal cancer cell line xenograft models harboring an APC mutation, but demonstrated little anti-tumor activity and led to intestinal toxicity (PMID: 26692561). 26692561
Clinical Trial Phase Therapies Title Recruitment Status